SecBot SecBot
PRESS-RELEASE ·Filed Jun 2, 2026

BVS

Bioventus, Inc.
BEARISH
Impact 6/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss is significant and likely to pressure the stock near-term. Monitor the upcoming Goldman Sachs conference for any guidance updates or strategic commentary that could clarify the miss.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.11
T+0 close · Jun 2, 2026 · via day close
Latest settled
+72.26%
T+60 · $13.97
Vs SPY
+71.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $8.11entry
  2. T+1 · 6mo ago +5.43%α +6.12% · $8.55
  3. T+5 · 5mo ago +13.44%α +16.41% · $9.20
  4. T+20 · 5mo ago +21.45%α +23.02% · $9.85
  5. T+60 · 3mo ago +72.26%α +71.14% · $13.97
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bioventus (BVS) reported Q1 2026 EPS of $0.15, a 30.6% miss versus the $0.22 consensus, on revenue of $155.4M (in line with the $155.4M estimate). The press release focuses on an upcoming conference appearance, not guidance or operational details, leaving the miss as the primary takeaway.

Key Financial Metrics

EPS
$0.15
est $0.22 · -31.8%
Revenue
$155.4M
est $155.4M · 0.0%
Rating
miss

Key Facts

  • Q1 2026 EPS of $0.15 missed consensus of $0.22 by 30.6%
  • Revenue of $155.4M was in line with consensus of $155.4M
  • No guidance update or operational commentary provided in the release
  • CFO to present at Goldman Sachs Global Healthcare Conference on June 8, 2026

Financial Impact

EPS miss of $0.07 per share vs consensus, representing a 30.6% shortfall

eps

Risk Factors

  • No guidance or operational context provided, leaving the miss unexplained
  • Potential for further downside if the miss reflects broader operational issues

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3304982

Track record

18 reports on BVS

Performance horizon

2 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +37.19% at T+60 after the May 8, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $10.66 Now $10.46 −1.88% settles Feb 11
  2. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $10.61 Now $10.46 −1.41% settles Feb 4
  3. Nov 2, 202614d ago 8-K Neutral 5/10 No price data
  4. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $10.95 Now $10.46 −4.43% settles Feb 1
  5. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $14.65 Now $10.46 −28.60% settles Jan 26
  6. Aug 15, 202613w ago Institutional Cluster Mixed 5/10 Entry $13.88 to $11.02 Now $10.46 −24.64% ▼ −20.64% −17.88% vs SPY
  7. Aug 5, 202614w ago 8-K Bullish 7/10 No price data
  8. Aug 5, 202614w ago Press Release Bullish 7/10 Entry $15.26 to $14.86 Now $10.46 −31.45% ▼ −2.62% −2.81% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $8.68 to $14.07 Now $10.46 −20.51% ▼ −62.10% −57.70% vs SPY
  10. Jun 2, 202623w ago Press Release Bearish 6/10 Viewing Entry $8.11 to $13.97 Now $10.46 −28.98% ▼ −72.26% −71.14% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 2, 2026